scholarly journals Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering

2006 ◽  
Vol 21 (4) ◽  
pp. 846-849 ◽  
Author(s):  
Toshio Miyata ◽  
Charles van Ypersele de Strihou
Keyword(s):  
Blood Pressure ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Blood Pressure Lowering ◽  
Pressure Lowering ◽  
Receptor Blockers

scholarly journals Renoprotective Properties of Angiotensin Receptor Blockers beyond Blood Pressure Lowering

2005 ◽  
Vol 16 (12) ◽  
pp. 3631-3641 ◽  
Author(s):  
Yuko Izuhara ◽  
Masaomi Nangaku ◽  
Reiko Inagi ◽  
Naoto Tominaga ◽  
Toru Aizawa ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Blood Pressure Lowering ◽  
Pressure Lowering ◽  
Receptor Blockers

scholarly journals Blood Pressure Control: Stroke and Stroke Prevention

2005 ◽  
Vol 6 (1_suppl) ◽  
pp. S8-S11
Author(s):  
Hans-Christoph Diener
Keyword(s):  
Blood Pressure ◽  
Stroke Prevention ◽  
Antihypertensive Drugs ◽  
Angiotensin Receptor Blockers ◽  
Antihypertensive Agents ◽  
Pressure Control ◽  
Angiotensin Receptor ◽  
Risk Of Death ◽  
Pressure Lowering ◽  
Receptor Blockers

Hypertension is the most important modifiable risk factor for primary and secondary stroke prevention. All antihypertensive drugs are effective in primary prevention: the risk reduction for stroke is 30—42%. However, not all classes of drugs have the same effects: there is some indication that angiotensin receptor blockers may be superior to other classes of antihypertensive drugs in stroke prevention. Seventy-five percent of patients who present to hospital with acute stroke have elevated blood pressure within the first 24—48 hours. Extremes of systolic blood pressure (SBP) increase the risk of death or dependency. The aim of treatment should be to achieve and maintain the SBP in the range 140—160 mmHg. However, fast and drastic blood pressure lowering can have adverse consequences. The PROGRESS trial of secondary prevention with perindopril + indapamide versus placebo + placebo showed a decrease in numbers of stroke recurrences in patients given both active antihypertensive agents, more impressive for cerebral haemorrhage.There were also indications that active treatment might decrease the development of post-stroke dementia.

scholarly journals ROADMAP and ORIENTAL Trials: The Re-emergence of J-Curve Ghost?

2011 ◽  
Vol 2 ◽  
pp. JCM.S7521 ◽  
Author(s):  
Yoshiyuki Hamamoto ◽  
Hiroyuki Koshiyama
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Events ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Blood Pressure Lowering ◽  
J Curve ◽  
Pressure Lowering ◽  
Risk Patients ◽  
Receptor Blockers

It still remains unknown whether angiotensin-receptor blockers (ARBs) are cardioprotective in patients with type 2 diabetes. The recent two clinical trials, the ROADMAP and the ORIENT, have suggested that fatal cardiovascular events or cardiovascular deaths were unexpectedly higher in olmesartan group. These results suggest that aggressive blood pressure lowering may cause a higher risk in some high-risk patients, especially in those with preexisting coronary heart disease, indicating a possibility that the J-curve phenomenon may exist in some group of patients.

Sign in / Sign up

Export Citation Format

Share Document